We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dr. Kevin P. Francis Ph.D, PerkinElmer Fellow and Visiting Professor at UCLA and Texas A&M / Dr. Guillaume Reveillon, PhD Field Application Specialist PerkinElmer
According to the World Health Organization, infectious diseases are estimated to cause a quarter of all deaths globally. Moreover, the risk of new pathogens emerging and evolving to monopolize on the ever-expanding global human population is increasing year-on-year. The recent COVID-19 viral pandemic, although devastating from both a social and economic standpoint, was relatively minor compared to prior viral and bacterial ‘plagues’ that have reshaped civilizations throughout history.
Each year more than 70 billion standard units of antibiotic are prescribed to treat bacterial infections worldwide. In addition, around 80,000 tons of antibiotics are consumed by livestock for growth promotion and disease prevention. The result of this overuse of antibiotics is a spiraling increase in resistance. Bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) have increased in prevalence in hospitals over the last three decades. Such bacteria are particularly problematic in postoperative infections, exacerbating treatment through the development of biofilms, especially on medical implants which are extremely hard to treat without removal and replacement of the device.
This presentation will show how noninvasive preclinical optical imaging is being used to better understand the establishment and development of infections in a range of different animal disease models, including post-operative infections
Host: Dr. Anna Santamaria, Biomedical Research in Urology group.
Online Connection: https://gencat.zoom.us/j/94191432677
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.